Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective June 15, 2015 (the “Effective Date” ), the board of directors (the “Board” ) of Anavex Life Sciences Corp., a Nevada corporation (the “Company” ), appointed Steffen Thomas, PhD, to serve as a member of the Board until his successor is duly elected, qualified and seated or until his earlier resignation or removal.
In addition to being a member of the Board, it is anticipated that Dr. Thomas will serve on the Audit Committee, effective as of the Effective Date. As compensation for his services, the Company granted Dr. Thomas options to purchase two hundred thousand (200,000) shares of common stock in the Company, said options to vest annually over a three year period commencing on the first anniversary of the Effective Date.
The Company has not entered into any transactions with Dr. Thomas that would require disclosure pursuant to Item 404(a) of Regulation S-K under the Exchange Act of 1934, as amended.
In the 10K. According to the last one (Sept 2014) Dr. Metzner is probably qualified to head an independent audit committee, but one had not been formed yet. Would love to know if one has, because it is necessary for uplisting.
Market Data 
Markets 
AI
